Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 44
Filter
Add more filters










Publication year range
1.
Front Immunol ; 14: 1094236, 2023.
Article in English | MEDLINE | ID: mdl-37564650

ABSTRACT

Introduction: Identification of tumor specific neoantigen (TSN) immunogenicity is crucial to develop peptide/mRNA based anti-tumoral vaccines and/or adoptive T-cell immunotherapies; thus, accurate in-silico classification/prioritization proves critical for cost-effective clinical applications. Several methods were proposed as TSNs immunogenicity predictors; however, comprehensive performance comparison is still lacking due to the absence of well documented and adequate TSN databases. Methods: Here, by developing a new curated database having 199 TSNs with experimentally-validated MHC-I presentation and positive/negative immune response (ITSNdb), sixteen metrics were evaluated as immunogenicity predictors. In addition, by using a dataset emulating patient derived TSNs and immunotherapy cohorts containing predicted TSNs for tumor neoantigen burden (TNB) with outcome association, the metrics were evaluated as TSNs prioritizers and as immunotherapy response biomarkers. Results: Our results show high performance variability among methods, highlighting the need for substantial improvement. Deep learning predictors were top ranked on ITSNdb but show discrepancy on validation databases. In overall, current predicted TNB did not outperform existing biomarkers. Conclusion: Recommendations for their clinical application and the ITSNdb are presented to promote development and comparison of computational TSNs immunogenicity predictors.


Subject(s)
Neoplasms , Humans , Antigens, Neoplasm , Peptides
2.
Nat Commun ; 14(1): 2537, 2023 05 03.
Article in English | MEDLINE | ID: mdl-37137944

ABSTRACT

The genomes of most protozoa encode families of variant surface antigens. In some parasitic microorganisms, it has been demonstrated that mutually exclusive changes in the expression of these antigens allow parasites to evade the host's immune response. It is widely assumed that antigenic variation in protozoan parasites is accomplished by the spontaneous appearance within the population of cells expressing antigenic variants that escape antibody-mediated cytotoxicity. Here we show, both in vitro and in animal infections, that antibodies to Variant-specific Surface Proteins (VSPs) of the intestinal parasite Giardia lamblia are not cytotoxic, inducing instead VSP clustering into liquid-ordered phase membrane microdomains that trigger a massive release of microvesicles carrying the original VSP and switch in expression to different VSPs by a calcium-dependent mechanism. This novel mechanism of surface antigen clearance throughout its release into microvesicles coupled to the stochastic induction of new phenotypic variants not only changes current paradigms of antigenic switching but also provides a new framework for understanding the course of protozoan infections as a host/parasite adaptive process.


Subject(s)
Giardia lamblia , Giardiasis , Intestinal Diseases, Parasitic , Parasites , Animals , Giardia lamblia/genetics , Giardia lamblia/metabolism , Parasites/metabolism , Antigens, Surface/genetics , Antigens, Surface/metabolism , Antigens, Protozoan , Antibodies/metabolism , Antigenic Variation , Protozoan Proteins/genetics , Protozoan Proteins/metabolism
3.
Genomics ; 114(5): 110462, 2022 09.
Article in English | MEDLINE | ID: mdl-35998788

ABSTRACT

Giardia lamblia encodes several families of cysteine-rich proteins, including the Variant-specific Surface Proteins (VSPs) involved in the process of antigenic variation. Their characteristics, definition and relationships are still controversial. An exhaustive analysis of the Cys-rich families including organization, features, evolution and levels of expression was performed, by combining pattern searches and predictions with massive sequencing techniques. Thus, a new classification for Cys-rich proteins, genes and pseudogenes that better describes their involvement in Giardia's biology is presented. Moreover, three novel characteristics exclusive to the VSP genes, comprising an Initiator element/Kozak-like sequence, an extended polyadenylation signal and a unique pattern of mutually exclusive transcript accumulation are presented, as well as the finding that High Cysteine Membrane Proteins, upregulated under stress, may protect the parasite during VSP switching. These results allow better interpretation of previous reports providing the basis for further studies of the biology of this early-branching eukaryote.


Subject(s)
Giardia lamblia , Antigenic Variation/genetics , Antigens, Protozoan , Antigens, Surface/genetics , Cysteine/genetics , Giardia lamblia/genetics , Giardia lamblia/metabolism , Membrane Proteins/genetics , Protozoan Proteins/genetics
4.
J Biol Chem ; 298(6): 102028, 2022 06.
Article in English | MEDLINE | ID: mdl-35568200

ABSTRACT

Giardiasis is a diarrheal disease caused by the unicellular parasite Giardia intestinalis, for which metronidazole is the main treatment option. The parasite is dependent on exogenous deoxyribonucleosides for DNA replication and thus is also potentially vulnerable to deoxyribonucleoside analogs. Here, we characterized the G. intestinalis thymidine kinase, a divergent member of the thymidine kinase 1 family that consists of two weakly homologous parts within one polypeptide. We found that the recombinantly expressed enzyme is monomeric, with 100-fold higher catalytic efficiency for thymidine compared to its second-best substrate, deoxyuridine, and is furthermore subject to feedback inhibition by dTTP. This efficient substrate discrimination is in line with the lack of thymidylate synthase and dUTPase in the parasite, which makes deoxy-UMP a dead-end product that is potentially harmful if converted to deoxy-UTP. We also found that the antiretroviral drug azidothymidine (AZT) was an equally good substrate as thymidine and was active against WT as well as metronidazole-resistant G. intestinalis trophozoites. This drug inhibited DNA synthesis in the parasite and efficiently decreased cyst production in vitro, which suggests that it could reduce infectivity. AZT also showed a good effect in G. intestinalis-infected gerbils, reducing both the number of trophozoites in the small intestine and the number of viable cysts in the stool. Taken together, these results suggest that the absolute dependency of the parasite on thymidine kinase for its DNA synthesis can be exploited by AZT, which has promise as a future medication effective against metronidazole-refractory giardiasis.


Subject(s)
DNA Replication , Giardia lamblia , Protozoan Proteins , Thymidine Kinase , Zidovudine , Animals , Drug Discovery , Gerbillinae , Giardia lamblia/enzymology , Giardia lamblia/genetics , Giardiasis/drug therapy , Metronidazole/therapeutic use , Protozoan Proteins/antagonists & inhibitors , Protozoan Proteins/genetics , Thymidine , Thymidine Kinase/antagonists & inhibitors , Thymidine Kinase/genetics , Zidovudine/pharmacology
5.
Front Immunol ; 13: 837443, 2022.
Article in English | MEDLINE | ID: mdl-35281065

ABSTRACT

An ideal protective vaccine against SARS-CoV-2 should not only be effective in preventing disease, but also in preventing virus transmission. It should also be well accepted by the population and have a simple logistic chain. To fulfill these criteria, we developed a thermostable, orally administered vaccine that can induce a robust mucosal neutralizing immune response. We used our platform based on retrovirus-derived enveloped virus-like particles (eVLPs) harnessed with variable surface proteins (VSPs) from the intestinal parasite Giardia lamblia, affording them resistance to degradation and the triggering of robust mucosal cellular and antibody immune responses after oral administration. We made eVLPs expressing various forms of the SARS-CoV-2 Spike protein (S), with or without membrane protein (M) expression. We found that prime-boost administration of VSP-decorated eVLPs expressing a pre-fusion stabilized form of S and M triggers robust mucosal responses against SARS-CoV-2 in mice and hamsters, which translate into complete protection from a viral challenge. Moreover, they dramatically boosted the IgA mucosal response of intramuscularly injected vaccines. We conclude that our thermostable orally administered eVLP vaccine could be a valuable addition to the current arsenal against SARS-CoV-2, in a stand-alone prime-boost vaccination strategy or as a boost for existing vaccines.


Subject(s)
COVID-19 Vaccines/immunology , COVID-19/immunology , Coronavirus M Proteins/immunology , Giardia lamblia/immunology , Intestinal Mucosa/immunology , SARS-CoV-2/physiology , Spike Glycoprotein, Coronavirus/immunology , Animals , Antigens, Protozoan/immunology , Cricetinae , Humans , Immunity , Immunization, Secondary , Immunoglobulin A/metabolism , Male , Mice , Mice, Inbred BALB C , Temperature , Vaccine Potency , Vaccines, Virus-Like Particle
6.
Brief Bioinform ; 22(4)2021 07 20.
Article in English | MEDLINE | ID: mdl-33320931

ABSTRACT

The accurate quantification of tumor-infiltrating immune cells turns crucial to uncover their role in tumor immune escape, to determine patient prognosis and to predict response to immune checkpoint blockade. Current state-of-the-art methods that quantify immune cells from tumor biopsies using gene expression data apply computational deconvolution methods that present multicollinearity and estimation errors resulting in the overestimation or underestimation of the diversity of infiltrating immune cells and their quantity. To overcome such limitations, we developed MIXTURE, a new ν-support vector regression-based noise constrained recursive feature selection algorithm based on validated immune cell molecular signatures. MIXTURE provides increased robustness to cell type identification and proportion estimation, outperforms the current methods, and is available to the wider scientific community. We applied MIXTURE to transcriptomic data from tumor biopsies and found relevant novel associations between the components of the immune infiltrate and molecular subtypes, tumor driver biomarkers, tumor mutational burden, microsatellite instability, intratumor heterogeneity, cytolytic score, programmed cell death ligand 1 expression, patients' survival and response to anti-cytotoxic T-lymphocyte-associated antigen 4 and anti-programmed cell death protein 1 immunotherapy.


Subject(s)
Databases, Nucleic Acid , Gene Expression Regulation, Neoplastic/immunology , Immunotherapy , Models, Immunological , Neoplasms , Support Vector Machine , Transcriptome/immunology , Humans , Neoplasms/genetics , Neoplasms/immunology , Neoplasms/therapy
7.
Medicina (B Aires) ; 79(Spec 6/1): 559-563, 2019.
Article in English | MEDLINE | ID: mdl-31864226

ABSTRACT

The international spread of infectious diseases is a global problem of health security. Vaccination is one of the most successful and profitable health interventions. Oral immunization has significant advantages over the widely used parental vaccines. Intestinal and free-living protozoa express on their surface a dense layer of proteins that protect them from hostile environmental conditions. The use of variable surface proteins (VSPs), such as those of the intestinal protozoan Giardia lamblia, is a feasible mechanism for the generation of oral vaccines, since they are highly immunogenic as well as resistant to changes in pH and proteases. In a recently published article, we showed that these properties of VSPs can be exploited to protect and enhance the immunogenicity of vaccine antigens, thus enabling their oral administration. We recently generated an oral vaccine against influenza virus composed of virus-like particles (VLPs) containing VSPs of G. lamblia and the HA antigen (viral hemagglutinin) in its envelope. When administered orally to mice, these coated particles elicit HA-specific humoral (systemic and local) and cellular responses, without the need of any additional adjuvant. Treated mice are protected against viral challenge as well as against the development of tumors expressing the HA vaccine antigen.


La propagación internacional de enfermedades infecciosas constituye un problema global de seguridad sanitaria. La vacunación es una de las intervenciones en salud más exitosas y efectivas. La administración por vía oral presenta ventajas significativas sobre la vía parental utilizada comúnmente. Protozoarios intestinales y de vida libre expresan en su superficie una densa capa de proteínas que los protegen de condiciones ambientales hostiles. La utilización de proteínas de superficie variante-específicas o VSPs (del inglés "Variant-specific Surface Proteins") tales como las del protozoario intestinal Giardia lamblia constituye un enfoque eficiente para la generación de vacunas orales, dada su alta inmunogenicidad y su resistencia a cambios de pH y proteasas. En un trabajo reciente mostramos que estas propiedades pueden ser explotadas para proteger antígenos vacunales y potenciar su inmunogenicidad, facilitando así su administración oral. Como modelo inicial, generamos una vacuna oral contra el virus de la influenza compuesta por partículas similares a virus (VLPs, del inglés "virus-like particles") que contienen en su envoltorio VSPs de G. lamblia y el antígeno HA (hemaglutinina del virus de la influenza). La administración oral a ratones de estas partículas recubiertas con VSPs y HA induce una respuesta inmune humoral (sistémica y de mucosa) y celular específica para HA sin la necesidad de adyuvantes externos. La respuesta inmune generada protege frente al desafío con el virus y también frente al desarrollo de tumores que expresan el antígeno vacunal HA.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Membrane Proteins/immunology , Protozoan Proteins/immunology , Vaccines, Virus-Like Particle/immunology , Vaccines/immunology , Administration, Oral , Animals , Giardia lamblia/chemistry , Humans , Immunity, Humoral/drug effects , Membrane Proteins/administration & dosage , Protozoan Proteins/administration & dosage , Vaccines/administration & dosage , Vaccines, Virus-Like Particle/administration & dosage
9.
Nat Commun ; 10(1): 361, 2019 01 21.
Article in English | MEDLINE | ID: mdl-30664644

ABSTRACT

Intestinal and free-living protozoa, such as Giardia lamblia, express a dense coat of variant-specific surface proteins (VSPs) on trophozoites that protects the parasite inside the host's intestine. Here we show that VSPs not only are resistant to proteolytic digestion and extreme pH and temperatures but also stimulate host innate immune responses in a TLR-4 dependent manner. We show that these properties can be exploited to both protect and adjuvant vaccine antigens for oral administration. Chimeric Virus-like Particles (VLPs) decorated with VSPs and expressing model surface antigens, such as influenza virus hemagglutinin (HA) and neuraminidase (NA), are protected from degradation and activate antigen presenting cells in vitro. Orally administered VSP-pseudotyped VLPs, but not plain VLPs, generate robust immune responses that protect mice from influenza infection and HA-expressing tumors. This versatile vaccine platform has the attributes to meet the ultimate challenge of generating safe, stable and efficient oral vaccines.


Subject(s)
Giardia lamblia/chemistry , Influenza Vaccines/immunology , Membrane Proteins/immunology , Orthomyxoviridae Infections/prevention & control , Protozoan Proteins/immunology , Vaccines, Virus-Like Particle/immunology , Adjuvants, Immunologic , Administration, Oral , Animals , Antigen Presentation/drug effects , Bioengineering/methods , Dendritic Cells/drug effects , Dendritic Cells/immunology , Dendritic Cells/virology , Female , Gene Expression , Hemagglutinin Glycoproteins, Influenza Virus/genetics , Hemagglutinin Glycoproteins, Influenza Virus/immunology , Humans , Immunity, Innate/drug effects , Influenza Vaccines/administration & dosage , Influenza Vaccines/genetics , Male , Membrane Proteins/genetics , Mice , Mice, Transgenic , Neuraminidase/genetics , Neuraminidase/immunology , Orthomyxoviridae Infections/immunology , Orthomyxoviridae Infections/virology , Protein Stability , Protozoan Proteins/genetics , Toll-Like Receptor 4/genetics , Toll-Like Receptor 4/immunology , Trophozoites/chemistry , Vaccination , Vaccines, Virus-Like Particle/administration & dosage , Vaccines, Virus-Like Particle/genetics
10.
Mol Biochem Parasitol ; 228: 16-26, 2019 03.
Article in English | MEDLINE | ID: mdl-30658179

ABSTRACT

Giardia lamblia is one of the most common protozoan infectious agents in the world and is responsible for diarrheal disease and chronic postinfectious illness. During the host-parasite interaction, proteases are important molecules related to virulence, invasion, and colonization, not only for Giardia but also for other parasites. We aimed to characterize the cysteine protease activity detected in trophozoite lysates. This proteolytic activity showed the ability to cleave NH-terminal sequences with either a recognition sequence for a viral protease or a recognition sequence for thrombin. This cleavage activity was detected in nonencysting trophozoites and increased with the progression of encystation. This activity was also detected in excretion/secretion products of axenic trophozoites and in trophozoites cocultured with differentiated Caco-2 cells. Based on size exclusion chromatography, we obtained a fraction enriched in low- to medium-molecular-weight proteins that was capable of exerting this cleavage activity and aggregating human platelets. Finally, our results suggest that this proteolytic activity is shared with other protozoan parasites.


Subject(s)
Cysteine Proteases/metabolism , Giardia lamblia/enzymology , Protozoan Proteins/metabolism , Caco-2 Cells , Cathepsin B/chemistry , Cathepsin B/genetics , Cathepsin B/metabolism , Cysteine Proteases/chemistry , Cysteine Proteases/genetics , Giardia lamblia/chemistry , Giardia lamblia/genetics , Giardiasis , Humans , Proteolysis , Protozoan Proteins/chemistry , Protozoan Proteins/genetics , Substrate Specificity , Trophozoites/chemistry , Trophozoites/enzymology , Trophozoites/genetics
11.
Front Immunol ; 9: 471, 2018.
Article in English | MEDLINE | ID: mdl-29662482

ABSTRACT

Tuberculosis remains a major global health problem and efforts to develop a more effective vaccine have been unsuccessful so far. Targeting antigens (Ags) to dendritic cells (DCs) in vivo has emerged as a new promising vaccine strategy. In this approach, Ags are delivered directly to DCs via antibodies that bind to endocytic cell-surface receptors. Here, we explored DC-specific-ICAM3-grabbing-nonintegrin (DC-SIGN) targeting as a potential vaccine against tuberculosis. For this, we made use of the hSIGN mouse model that expresses human DC-SIGN under the control of the murine CD11c promoter. We show that in vitro and in vivo delivery of anti-DC-SIGN antibodies conjugated to Ag85B and peptide 25 of Ag85B in combination with anti-CD40, the fungal cell wall component zymosan, and the cholera toxin-derived fusion protein CTA1-DD induces strong Ag-specific CD4+ T-cell responses. Improved anti-mycobacterial immunity was accompanied by increased frequencies of Ag-specific IFN-γ+ IL-2+ TNF-α+ polyfunctional CD4+ T cells in vaccinated mice compared with controls. Taken together, in this study we provide the proof of concept that the human DC-SIGN receptor can be efficiently exploited for vaccine purposes to promote immunity against mycobacterial infections.


Subject(s)
Antigens, Bacterial/immunology , Cell Adhesion Molecules/immunology , Dendritic Cells/immunology , Immunity, Cellular , Lectins, C-Type/immunology , Mycobacterium tuberculosis/immunology , Receptors, Cell Surface/immunology , Th1 Cells/immunology , Tuberculosis Vaccines/immunology , Animals , Cytokines/immunology , Dendritic Cells/pathology , Humans , Mice , Th1 Cells/pathology , Tuberculosis/immunology , Tuberculosis/prevention & control
12.
Infect Immun ; 86(6)2018 06.
Article in English | MEDLINE | ID: mdl-29555679

ABSTRACT

Giardiasis is one of the most common human intestinal diseases worldwide. Several experimental animal models have been used to evaluate Giardia infections, with gerbils (Meriones unguiculatus) being the most valuable model due to their high susceptibility to Giardia infection, abundant shedding of cysts, and pathophysiological alterations and signs of disease similar to those observed in humans. Here, we report cytokine and antibody profiles both during the course of Giardia infection in gerbils and after immunization with a novel oral vaccine comprising a mixture of purified variant-specific surface proteins (VSPs). Transcript levels of representative cytokines of different immune profiles as well as macro- and microtissue alterations were assessed in Peyer's patches, mesenteric lymph nodes, and spleens. During infection, cytokine responses showed a biphasic profile: an early induction of Th1 (gamma interferon [IFN-γ], interleukin-1ß [IL-1ß], IL-6, and tumor necrosis factor [TNF]), Th17 (IL-17), and Th2 (IL-4) cytokines, together with intestinal alterations typical of inflammation, followed by a shift toward a predominant Th2 (IL-5) response, likely associated with a counterregulatory mechanism. Conversely, immunization with an oral vaccine comprising the entire repertoire of VSPs specifically showed high levels of IL-17, IL-6, IL-4, and IL-5, without obvious signs of inflammation. Both immunized and infected animals developed local (intestinal secretory IgA [S-IgA]) and systemic (serum IgG) humoral immune responses against VSPs; however, only infected animals showed evident signs of giardiasis. This is the first comprehensive report of cytokine expression and anti-Giardia antibody production during infection and VSP vaccination in gerbils, a reliable model of the human disease.


Subject(s)
Giardia lamblia/genetics , Giardiasis/prevention & control , Membrane Proteins/genetics , Protozoan Vaccines/immunology , Animals , Female , Gerbillinae , Giardiasis/parasitology , Humans , Male , Membrane Proteins/immunology , Organisms, Genetically Modified , Specific Pathogen-Free Organisms , Vaccination
13.
Int J Biochem Cell Biol ; 81(Pt A): 32-43, 2016 12.
Article in English | MEDLINE | ID: mdl-27771437

ABSTRACT

During evolution, parasitic microorganisms have faced the challenges of adapting to different environments to colonize a variety of hosts. Giardia lamblia, a common cause of intestinal disease, has developed fascinating strategies to adapt both outside and inside its host's intestine, such as trophozoite differentiation into cyst and the switching of its major surface antigens. How gene expression is regulated during these adaptive processes remains undefined. Giardia lacks some typical eukaryotic features, like canonical transcription factors, linker histone H1, and complex promoter regions; suggesting that post-transcriptional and translational control of gene expression is essential for parasite survival. However, epigenetic factors may also play critical roles at the transcriptional level. Here, we describe the most common post-translational histone modifications; characterize enzymes involved in these reactions, and analyze their association with the Giardia's differentiation processes. We present evidence that NAD+-dependent and NAD+-independent histone deacetylases regulate encystation; however, a unique NAD+-independent histone deacetylase modulate antigenic switching. The rates of acetylation of H4K8 and H4K16 are critical for encystation, whereas a decrease in acetylation of H4K8 and methylation of H3K9 occur preferentially during antigenic variation. These results show the complexity of the mechanisms regulating gene expression in this minimalistic protozoan parasite.


Subject(s)
Antigenic Variation , Giardia lamblia/immunology , Giardia lamblia/metabolism , Histones/metabolism , Acetylation/drug effects , Antigenic Variation/drug effects , Euchromatin/metabolism , Giardia lamblia/cytology , Giardia lamblia/genetics , Heterochromatin/metabolism , Histone Deacetylase Inhibitors/pharmacology , Histone Deacetylases/metabolism , Histones/chemistry , Lysine/metabolism , NAD/metabolism , Protein Processing, Post-Translational/drug effects
14.
NPJ Vaccines ; 1: 16018, 2016.
Article in English | MEDLINE | ID: mdl-29263857

ABSTRACT

Giardia lamblia is a human intestinal parasite and one of the most frequent enteric pathogen of companion animals. Clinical manifestations of giardiasis, such as diarrhoea, anorexia, weight loss and lethargy, have been associated with Giardia infections in both domestic and farm animals. A few anti-parasitic drugs are routinely used to treat giardiasis, but re-infections are common and drug-resistant strains have already been reported. Unfortunately, efficient vaccines against Giardia are not available. Giardia undergoes antigenic variation; through this mechanism, parasites can avoid the host's immune defenses, causing chronic infections and/or re-infections. Antigenic variation is characterised by a continuous switch in the expression of members of a homologous family of genes encoding surface antigens. In a previous report, we indicated that in Giardia, the mechanism responsible for the exchange of variant-specific surface proteins (VSPs) involves the RNA interference (RNAi) pathway. From a repertoire of ~200 VSP genes, only one is expressed on the surface of single trophozoites; however, RNAi machinery disruption generates trophozoites that express the complete VSP repertoire. We also demonstrated that gerbils orally immunised with VSPs isolated from these altered parasites showed high levels of protection. Here we tested this vaccine in cats and dogs, and found that it is highly efficient in preventing new infections and reducing chronic giardiasis in domestic animals both in experimental and natural infections. Remarkably, immunisation of dogs in a highly endemic area strongly decreased the percentage of infected children in the community, suggesting that this vaccine would block the zoonotic transmission of the disease.

15.
BMC Microbiol ; 12: 284, 2012 Nov 28.
Article in English | MEDLINE | ID: mdl-23190735

ABSTRACT

BACKGROUND: Regulation of surface antigenic variation in Giardia lamblia is controlled post-transcriptionally by an RNA-interference (RNAi) pathway that includes a Dicer-like bidentate RNase III (gDicer). This enzyme, however, lacks the RNA helicase domain present in Dicer enzymes from higher eukaryotes. The participation of several RNA helicases in practically all organisms in which RNAi was studied suggests that RNA helicases are potentially involved in antigenic variation, as well as during Giardia differentiation into cysts. RESULTS: An extensive in silico analysis of the Giardia genome identified 32 putative Super Family 2 RNA helicases that contain almost all the conserved RNA helicase motifs. Phylogenetic studies and sequence analysis separated them into 22 DEAD-box, 6 DEAH-box and 4 Ski2p-box RNA helicases, some of which are homologs of well-characterized helicases from higher organisms. No Giardia putative helicase was found to have significant homology to the RNA helicase domain of Dicer enzymes. Additionally a series of up- and down-regulated putative RNA helicases were found during encystation and antigenic variation by qPCR experiments. Finally, we were able to recognize 14 additional putative helicases from three different families (RecQ family, Swi2/Snf2 and Rad3 family) that could be considered DNA helicases. CONCLUSIONS: This is the first comprehensive analysis of the Super Family 2 helicases from the human intestinal parasite G. lamblia. The relative and variable expression of particular RNA helicases during both antigenic variation and encystation agrees with the proposed participation of these enzymes during both adaptive processes. The putatives RNA and DNA helicases identified in this early-branching eukaryote provide initial information regarding the biological role of these enzymes in cell adaptation and differentiation.


Subject(s)
Antigenic Variation , DNA Helicases/metabolism , Giardia lamblia/enzymology , Giardia lamblia/growth & development , RNA Helicases/metabolism , Spores, Protozoan/growth & development , Computational Biology , DNA Helicases/genetics , Genome, Protozoan/genetics , Giardia lamblia/genetics , RNA Helicases/genetics , Spores, Protozoan/enzymology
16.
FEMS Microbiol Lett ; 335(2): 123-9, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22835260

ABSTRACT

Trypanosomatids are unicellular protozoan parasites that cause many diseases in animals, including humans, and plants. These early divergent eukaryotes have many singular structures and processes, including the hyper-modified 'base J', a mitochondrial DNA network, RNA editing, and trans-splicing; all of these unique features involve a wide variety of specific DNA/RNA helicases. In this work, the genomes of trypanosomatids were analyzed by data mining, searching for genes coding for DNA/RNA helicases. Specific motifs and full-length sequences from all families present in the helicase's superfamilies (SFs) 1 and 2 were used as baits for genome analyses. A total of 328 putative helicases were identified; 204 genes were assigned to the SF2, 42 genes to the SF1, and 76 genes remain unclassified. Eight species-specific SF2 helicases were also found; Trypanosoma cruzi has three DEAD-box and one DEAH/RHA-specific helicases, while Leishmania major has three Swi2/Snf2 and Trypanosoma brucei has only one RigI helicase. Finally, to identify helicases that could be used as future therapeutic targets, all obtained genes were compared with those present in the human genome. Forty-two helicases underrepresented in the human genome were identified; constituting 16 orthologs groups from L. major, T. brucei, and T. cruzi.


Subject(s)
DNA Helicases/genetics , RNA Helicases/genetics , Trypanosomatina/enzymology , Amino Acid Sequence , Cluster Analysis , Computer Simulation , DNA Helicases/metabolism , Genome , Genomics , Humans , Molecular Sequence Data , Phylogeny , RNA Helicases/metabolism , Species Specificity , Trypanosomatina/genetics
18.
19.
Acta Trop ; 123(1): 39-46, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22498829

ABSTRACT

Giardia intestinalis is considered an early-branching eukaryote and is therefore a valuable model for studying primordial cellular processes. This work reports the characterization of the ubiquitin-activating enzyme (E1) during growth and different stages of trophozoite differentiation into cysts. We found that in Giardia E1 expression (both at mRNA and protein levels) is regulated during encystation. The enzyme is proteolytically processed mainly into two fragments of 68kDa (N-terminal) and 47kDa (C-terminal). This phenomenon has not been described for any other E1. In trophozoites, this enzyme localized at spots within the cytoplasm as detected by using polyclonal antibodies against either E1 N- or C-terminal fragments. This pattern changed during encystation into a diffuse localization throughout the cytoplasm of encysting cells. E1 localizes in mature cysts at cytoplasmic spots and in the cyst wall. Our antisense silencing experiments suggested that E1 is an essential gene for parasite viability. On the other hand, E1 over-expression greatly increased the encystation rate, indicating a relationship between E1 and Giardia differentiation.


Subject(s)
Giardia lamblia/enzymology , Giardia lamblia/growth & development , Ubiquitin-Activating Enzymes/metabolism , Animals , Female , Gene Expression Profiling , Gene Expression Regulation , Mice , Mice, Inbred BALB C , Microbial Viability , Proteolysis , Spores, Protozoan/enzymology , Spores, Protozoan/growth & development , Trophozoites/enzymology , Trophozoites/growth & development
20.
Essays Biochem ; 51: 177-91, 2011.
Article in English | MEDLINE | ID: mdl-22023449

ABSTRACT

Giardia lamblia, a parasite of humans, is a major source of waterborne diarrhoeal disease. Giardia is also an excellent system to study basic biochemical processes because it is a single-celled eukaryote with a small genome and its entire life cycle can be replicated in vitro. Giardia trophozoites undergo fundamental changes to survive outside the intestine of their host by differentiating into infective cysts. Encystation entails the synthesis, processing, transport, secretion and extracellular assembly of cyst wall components. To survive within the intestine, Giardia undergoes antigenic variation, a process by which the parasite continuously switches its major surface molecules, allowing the parasite to evade the host's immune response and produce chronic and recurrent infections. The objective of the present chapter is to provide a better understanding of the molecular mechanisms involved in adaptation and differentiation in Giardia, with a particular focus on the process of encystation and antigenic variation of this interesting micro-organism.


Subject(s)
Adaptation, Physiological , Antigenic Variation , Giardia lamblia/physiology , Animals , Disease Models, Animal , Gene Expression Regulation , Giardia lamblia/pathogenicity , Giardiasis/parasitology , Host-Parasite Interactions , Humans , Life Cycle Stages , Protozoan Proteins/genetics , Protozoan Proteins/metabolism , RNA Interference
SELECTION OF CITATIONS
SEARCH DETAIL
...